Soluble receptor for urokinase plasminogen activator in community-acquired pneumonia in children

Advances in Experimental Medicine and Biology

Volumn 788, Issue , 2013, Pages 329-334

  Wrotek, A ^a,b   Pawlik, K ^a,b   Jackowska, T ^a,b  

^a MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^b BIELANSKI HOSPITAL   (Poland)

Author keywords

Children; Community acquired pneumonia; Inflammatory markers; Soluble urokinase plasminogen activator receptor (suPAR); White blood cell

Indexed keywords

C REACTIVE PROTEIN; PROCALCITONIN; SOLUBLE UROKINASE RECEPTOR; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ADOLESCENT; AGE; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL PRACTICE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; INFANT; LEUKOCYTE DIFFERENTIAL COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SCHOOL CHILD;

EID: 84881043044     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-94-007-6627-3_44     Document Type: Article

References (22)

1. Backes, Y., van der Sluijs, K. F., Mackie, D. P., Tacke, F., Koch, A., Tenhunen, J. J., & Schultz, M. J. (2012). Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: A systematic review. Intensive Care Medicine, 38, 1418-1428.
2. Blasi, F., & Carmeliet, P. (2002). uPAR: A versatile signalling orchestrator. Nature Reviews Molecular Cell Biology, 3, 932-943. (Pubitemid 35477371)
3. De Witte, H., Sweep, F., Brunner, N., Heuvel, J., Beex, L., Grebenschikov, N., & Benraad, T. (1998). Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assay. International Journal of Cancer, 77, 236-242. (Pubitemid 28287976)
4. Eugen-Olsen, J., Gustafson, P., Sidenius, N., Fischer, T. K., Parner, J., Aaby, P., Gomes, V. F., & Lisse, I. (2002). The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: A community study from Guinea-Bissau. The International Journal of Tuberculosis and Lung Disease, 6, 686-692. (Pubitemid 34832148)
5. Fevang, B., Eugen-Olsen, J., Yndestad, A., Brosstad, F., Beiske, K., Aukrust, P., & Froland, S. S. (2009). Enhanced levels of urokinase plasminogen activator and its soluble receptor in common variable immunodeficiency. Clinical Immunology, 131, 438-446.
6. Garcia-Monco, J. C., Coleman, J. L., & Benach, J. L. (2002). Soluble urokinase receptor (uPAR, CD87) is present in serum and cerebrospinal fluid in patients with neurologic diseases. Journal of Neuroimmunology, 129, 216-223. (Pubitemid 34874926)
7. Gyetko, M. R., Sud, S., Kendall, T., Fuller, J. A., Newstead, M. W., & Standiford, T. J. (2000). Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection. Journal of Immunology, 165, 1513-1519. (Pubitemid 30604586)
8. Huai, Q., Mazar, A. P., Kuo, A., Parry, G. C., Shaw, D. E., Callahan, J., Li, Y., Yuan, C., Bian, C., Chen, L., Furie, B., Furie, B. C., Cines, D. B., & Huang, M. (2006). Structure of human urokinase plasminogen activator in complex with its receptor. Science, 311, 656-659. (Pubitemid 43191309)
9. Huttunen, R., Syrjanen, J., Vuento, R., Hurme, M., Huhtala, H., Laine, J., Pessi, T., & Aittoniemi, J. (2011). Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: A prospective cohort study. Journal of Internal Medicine, 270, 32-40.
10. Kofoed, K., Andersen, O., Kronborg, G., Tvede, M., Petersen, J., Eugen-Olsen, J., & Larsen, K. (2007). Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: A prospective study. Critical Care, 11, R38.
11. Lawn, S. D., Myer, L., Bangani, N., Vogt, M., & Wood, R. (2007). Plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) and early mortality risk among patients enrolling for antiretroviral treatment in South Africa. BioMed Central Infectious Diseases, 7, 41.
12. Li, H., Luo, Y. F., Blackwell, T. S., & Xie, C. M. (2011). Meta-analysis and systematic review of procalcitoninguided therapy in respiratory tract infections. Antimicrobial Agents and Chemotherapy, 55, 5900-5906.
13. Ostergaard, C., Benfield, T., Lundgren, J. D., & Eugen-Olsen, J. (2004). Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome. Scandinavian Journal of Infectious Diseases, 36, 14-19. (Pubitemid 38219765)
14. Ostrowski, S. R., Piironen, T., Hoyer-Hansen, G., Gerstoft, J., Pedersen, B. K., Akanmori, B. D., & Kurtzhals, J. A. (2005). High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients. Journal of Acquired Immune Deficiency Syndromes, 39, 23-31. (Pubitemid 40617015)
15. Perch, M., Kofoed, P., Fischer, T. K., Co, F., Rombo, L., Aaby, P., & Eugen-Olsen, J. (2004). Serum level of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection. Parasite Immunology, 26, 207-211. (Pubitemid 39440864)
16. Plesner, T., Behrendt, N., & Ploug, M. (1997). Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. Stem Cells, 15, 398-408. (Pubitemid 27513714)
17. Rijneveld, A. W., Levi, M., Florquin, S., Speelman, P., Carmeliet, P., & van der Poll, T. (2002). Urokinse receptor is necessary for adequate host defense against pneumococcal pneumonia. Journal of Immunology, 168, 3507-3511. (Pubitemid 34250418)
18. Rudan, I., Boschi-Pinto, C., Biloglav, Z., Mulholland, K., & Campbell, H. (2008). Epidemiology and etiology of childhood pneumonia. Bulletin of the World Health Organization, 86, 408-416. (Pubitemid 351694322)
19. Sidenius, N., Sier, C. F., Ullum, H., Pedersen, B. K., Lepri, A. C., Blasi, F., & Eugen-Olsen, J. (2000). Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood, 96, 4091-4095.
20. Thuno, M., Macho, B., & Eugen-Olse, J. (2009). suPAR: The molecular crystal ball. Disease Markers, 27, 157-172.
21. Wiersinga, W. J., Kaqer, L. M., Hovius, J. W., ven der Windt, G. J., de Vos, A. F., Meijers, J. C., Roelofs, J. J., Dondorp, A., Levi, M., Day, N. P., Peacock, S. J., & van der Poll, T. (2010). Urokinase receptor is necessary for bacterial defense against pneumonia-derived septic melioidosis by facilitating phagocytosis. Journal of Immunology, 184, 3079-3086.
22. Wittenhagen, P., Andersen, J. B., Hansen, A., Lindholm, L., Ronne, F., Theil, J., Tvede, M., & Eugen-Olsen, J. (2011). Plasma soluble urokinase plasminogen activator receptor in children with urinary tract infection. Biomark Insights, 6, 79-82.